Ziprasidone for the treatment of generalized anxiety comorbidity in patients with bipolar disorder

Trial Profile

Ziprasidone for the treatment of generalized anxiety comorbidity in patients with bipolar disorder

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2014

At a glance

  • Drugs Ziprasidone (Primary)
  • Indications Bipolar disorders; Generalised anxiety disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jan 2009 Status changed from recruiting to discontinued, as per ClinicalTrials.gov record.
    • 22 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top